Cargando…
Melanoma-Specific Clinical Outcomes of Inpatient Immune Checkpoint Blockade Treatment
BACKGROUND: Little is known about patient outcomes with advanced melanoma following inpatient initiation or continuation of immune checkpoint blockade (ICB). METHODS AND RESULTS: We conducted a single institution retrospective case series of advanced melanoma patients who initiated ICB as an inpatie...
Autores principales: | Loo, Kimberly, Kalvin, Hannah L, Panageas, Katherine S, Park, Vivian, Postow, Michael A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438908/ https://www.ncbi.nlm.nih.gov/pubmed/35766876 http://dx.doi.org/10.1093/oncolo/oyac121 |
Ejemplares similares
-
Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma
por: Loo, Kimberly, et al.
Publicado: (2022) -
Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade
por: Fox, Douglas B., et al.
Publicado: (2023) -
Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma
por: Bolte, Laura A., et al.
Publicado: (2023) -
Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade
por: Yoo, Seong-Keun, et al.
Publicado: (2022) -
Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade
por: Jelinic, Petar, et al.
Publicado: (2018)